NATCO Pharma Limited (NATCOPHARM) Financial History

Name: NATCO Pharma Limited (NATCOPHARM) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

NATCO Pharma Limited (NATCOPHARM) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Hyderabad, India with about 4,433 employees. Its market capitalization is roughly ₹148 billion. In the fiscal year ended 2026-03-31, NATCOPHARM reported ₹40.4B in revenue and ₹14.2B in net income.

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally.

Interactive charts & full statements →

NATCOPHARM Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹40.4B	₹44.1B	₹39.8B	₹27.0B
Gross Profit	₹31.2B	₹35.5B	₹31.2B	₹19.5B
Operating Income (EBIT)	₹12.6B	₹19.8B	₹15.8B	₹7.9B
Net Income	₹14.2B	₹18.9B	₹13.9B	₹7.2B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NATCOPHARM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹7.4B	₹7.4B	₹6.5B	₹13.6B	₹13.3B
Gross Profit	₹5.9B	₹5.8B	₹5.1B	₹11.9B	₹11.0B
Operating Income (EBIT)	₹1.4B	₹772M	₹1.1B	₹5.3B	₹5.1B
Net Income	₹2.1B	₹2.7B	₹1.5B	₹5.2B	₹4.8B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NATCOPHARM Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹902M)	(₹1.1B)	(₹1.7B)	(₹1.0B)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NATCOPHARM Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹110.7B	₹86.3B	₹69.1B	₹56.6B	—
Total Liabilities	₹18.5B	₹10.2B	₹10.5B	₹7.8B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NATCOPHARM viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

4547 · Kissei Pharmaceutical Co., Ltd. — JPY 168 billion
COHANCE · Cohance Lifesciences Limited — ₹168 billion
APLLTD · Alembic Pharmaceuticals Limited — ₹166 billion
4521 · Kaken Pharmaceutical Co., Ltd. — JPY 151 billion
SUDEEPPHRM · Sudeep Pharma Limited — ₹130 billion
AKUMS · Akums Drugs and Pharmaceuticals Limited — ₹120 billion
4534 · Mochida Pharmaceutical Co., Ltd. — JPY 116 billion
STAR · Strides Pharma Science Limited — ₹112 billion

← NATCAPSUQ All “N” companies NATH →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.